|Year : 2021 | Volume
| Issue : 2 | Page : 155-166
Current global status and future development of traditional Chinese medicine in the prevention and treatment of coronavirus disease 2019
Ze-Jia Song1, Wan Najbah Nik Nabil2, Zhi-Chao Xi1, Hong-Xi Xu3
1 School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China
2 School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China; Pharmaceutical Services Program, Ministry of Health, Petaling Jaya, Malaysia
3 School of Pharmacy, Shanghai University of Traditional Chinese Medicine; Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
|Date of Submission||26-Apr-2020|
|Date of Acceptance||21-May-2020|
|Date of Web Publication||24-Mar-2021|
Prof. Hong-Xi Xu
Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203
Prof. Zhi-Chao Xi
School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203
Source of Support: None, Conflict of Interest: None
Recognizing the potential of globalizing traditional Chinese medicine (TCM) for coronavirus disease 2019 (COVID-19), this review summarizes the current global use of TCM for COVID-19, status of the internationalization of TCM, and strategy on globalizing TCM for COVID-19. COVID-19 is a novel coronavirus disease that has sparked a pandemic in March 2020 affecting over 110 countries. Although researchers have been racing to develop targeted anti-COVID-19 treatment and vaccine, they are still currently unavailable. Thus, in treating patients infected with COVID-19, western medicine mainly recommended symptomatic treatment and monitoring. Existing drugs are used in the context of clinical trials, and the FDA still not yet approved these drugs for COVID-19. On the other hand, TCM proposed herbal treatment for suspected individuals to take within their observation period, as well as for confirmed COVID-19 patients to take during active phase of disease and during recovery. In China, Integrative Chinese-Western Medicine had been used in treating 91.5% of COVID-19 patients and showed its strength in reducing disease severity, shortening recovery time, and lowering the mortality rate. Despite obstacles in globalizing TCM for the treatment of COVID-19, promoting appropriate use of locally registered TCM products may prevent disease in susceptible individuals, improve the quality of life, and assist in the recovery of COVID-19 patients. With increasing global acceptance, TCM may play a more important role in the battle against infectious disease in the future.
Keywords: Coronavirus disease 2019, coronavirus pneumonia, traditional Chinese medicine, traditional Chinese medicine globalization
|How to cite this article:|
Song ZJ, Nik Nabil WN, Xi ZC, Xu HX. Current global status and future development of traditional Chinese medicine in the prevention and treatment of coronavirus disease 2019. World J Tradit Chin Med 2021;7:155-66
|How to cite this URL:|
Song ZJ, Nik Nabil WN, Xi ZC, Xu HX. Current global status and future development of traditional Chinese medicine in the prevention and treatment of coronavirus disease 2019. World J Tradit Chin Med [serial online] 2021 [cited 2021 Jun 16];7:155-66. Available from: https://www.wjtcm.net/text.asp?2021/7/2/155/316614
| Introduction|| |
A novel coronavirus disease, coronavirus disease 2019 (COVID-19), was declared as a pandemic by the World Health Organization (WHO) on March 12, 2020, affecting 114 countries with a total of 118,000 reported cases and 4291 fatalities. As of May 17, 2020, the global statistics has mounted up to 4,534,731 confirmed cases and 307,537 deaths, striking 216 countries or territories. The most heavily affected country is the United States of America (USA), with 1,409,452 cases and 85,860 deaths. The symptoms manifested by contracted patients include the common respiratory infection symptoms, such as fever, cough, sputum production, lethargy, and dyspnea, as well as other symptoms such as headache, diarrhea, and myalgia.,
While laboratory tests involving real-time reverse-transcription polymerase chain reaction and serological testing are conducted to confirm COVID-19 cases, a minute fraction (1%) of patients had positive results but were asymptomatic yet contagious. Nevertheless, in addressing the COVID-19 outbreak, the WHO treatment guidelines mainly concentrate on symptomatic care as the FDA-approved vaccines and anti-COVID-19 medications are still lacking. Of 44 vaccine candidates, only mRNA-1273 (NCT04283461) and Ad5-nCOV (ChiCTR2000030906) are undergoing phase I clinical trials, which are only due to be completed in December 2020 and June 2021, respectively., The USA's Centers for Disease Control and Prevention outlined that the current preferred drugs for treating COVID-19 are remdesivir, an experimental intravenous antiviral, as well as hydroxychloroquine and chloroquine, which are oral antimalarial formulations that have been repurposed for COVID-19. In the United Kingdom (UK), however, the latter has been reserved for use in clinical trial contexts by the UK Medicines and Healthcare Products Regulatory Agency. On March 18, 2020, the WHO launched a “Solidarity” clinical study, in attempt to find an effective treatment for COVID-19, drawing participation from over 70 countries. The ongoing global trial investigates four promising drugs, namely remdesivir, lopinavir/ritonavir, interferon-β, hydroxychloroquine, and chloroquine.
Learning from experiences during the severe acute respiratory syndrome (SARS) outbreak, in China's battle against COVID-19, the Chinese government strongly advocated the integrative use of traditional Chinese medicine (TCM) alongside western medicine in the management of COVID-19. Accordingly, on January 27, 2020, the National Health Commission (NHC) of the People's Republic of China promoted the vigorous and integrative use of TCM and issued the 4th version of COVID-19 treatment guidelines which included the TCM treatment regimens. The recommended TCM treatments were divided into two categories – suspected COVID-19 cases and confirmed COVID-19 cases. The recommended TCM use in suspected cases aimed to delay progression to confirmed cases. Five patent TCM medicines were recommended for symptom control of suspected cases. On the other hand, TCM treatments for confirmed cases were further stratified into disease severity (mild, moderate, and severe) and according to TCM syndrome differentiation. Furthermore, TCM treatment was recommended for recovering COVID-19 patients. The treatment guidelines have been constantly updated with more corresponding TCM managements as more information regarding the disease comes to light and is currently in its 7th version. Although the disease categories in the 4th and 7th versions were similar, the latest version introduced TCM treatment for critical patients and included more syndrome differentiation. The 7th version also focused more on treating recovering COVID-19 patients, with different TCM herbal formulae being recommended based on the patients' syndrome differentiation and clinical manifestation.
TCM has been assimilated into hospitals in China, providing Integrative Chinese-Western Medicine (ICWM) treatment in both outpatient and inpatient settings. Early integration of TCM was evident from the China national guideline that was released in January 2020, which already recommended the usage of TCM for COVID-19. More than 90% of confirmed cases received TCM, which may have contributed to the relatively lower mortality rate (about 4%) in China. Recognizing the potential of TCM in preventing and treating COVID-19, we herein discuss the current global use of TCM, its challenges and strategies in addressing COVID-19, and future directions in this area.
| Current Use of Traditional Chinese Medicine for Coronavirus Disease 2019 in Mainland, China|| |
China's cumulated evidence and clinical benefits of integrating TCM and western medicine in managing the preceding SARS epidemic outbreak, served as a foundation in incorporating TCM into its national treatment guidelines for COVID-19 alongside western medicine., The extensive use of TCM-western medicine was announced by the NHC of the People's Republic of China on March 3, 2020, where 91.5% of confirmed COVID-19 cases (equivalent to 74,187 patients) and 90.6% of Hubei COVID-19 patients (equivalent to 61,449 patients) had received TCM treatment, which yielded over 90% of total effective rate., [Table 1] shows the detailed applications and scientific evidence for the possible beneficial effect of TCM for COVID-19 in China.
|Table 1: Current application and evidence of possible beneficial effect of traditional Chinese medicine in China on coronavirus disease 2019|
Click here to view
Use and evidence of traditional Chinese medicine in managing coronavirus disease 2019
China's NHC and State Administration of Traditional Chinese Medicine recommended prescribing TCM as per the disease severity (mild, moderate, severe, and critical), and as per the TCM syndrome differentiation pattern diagnosis classification, and according to the local climate and personal health conditions. The latest version of the treatment guidelines, Version 7 recommended Qing Fei Pai Du (lung-cleansing and toxin-removing) decoction to all suitable mild, moderate, severe, and critical COVID-19 patients. In the latest version, TCM herbal formulae generally include Ma Huang (Herba Ephedra), Shi Gao (Gypsum), Hou Po (Cortex Magnolia officinalis), Ting Li Zi (Semen Lepidii), Gan Cao (Glycyrrhizae Radix Rhizoma), and Huang Qin (Radix Scutellaria baicalensis) among other herbs recommended for confirmed cases. The ethanol extract of Huang Qin (Radix Scutellaria baicalensis) was found to impair the activity of SARS coronavirus 2 (SARS-CoV-2) 3CLpro (main protease of SARS-CoV-2) in vitro and block the replication of SARS-CoV-2 in the Vero cells at EC50 of 0.74 μg/mL. Baicalein, the primary constituent of Scutellaria baicalensis, highly suppressed the activity of SARS-CoV-2 3CLpro at IC50 of 0.39 μM. The study additionally discovered four baicalein analog compounds from other herbs that disrupt the activity of SARS-CoV-2 3CLpro at micromolar concentrations. Taken together, these findings suggest the potent anti-SARS-CoV-2 activity of the extract and compounds from Huang Qin (Radix Scutellaria baicalensis), as well as baicalein analogs.
The recommended Chinese patent medicine in severe cases diagnosed with the syndrome of flaring heat in Qi Fen and Ying Fen are Xiyan Ping injection, Xue Bijing injection, Reduning injection, Tan Re Qing injection, and Xing Nao Jing injection. For critical cases with the syndrome of inner blocking causing collapse, the Chinese patent medicines Su He Xiang pill (Storax), An Gong Niu Huang (Peaceful Palace Bovine Bezoar) pill, Xue Bi Jing injection, Reduning injection, Tan Re Qing injection, Xiao Nao Jing injection, Shen Fu injection, or Sheng Mai injection are recommended. Based on encouraging clinical evidence of Jin Hua Qing Gan (honeysuckle flower cold-relieving) capsule, Lian Hua Qing Wen (Forsythiae and honey flower pestilence-clearing) granule and capsule, and Xue Bi Jing injection in treating COVID-19 patients in China, the China National Administration of Traditional Chinese Medicine approved the indication of COVID-19 to be added to these three TCM patent medications.
Recent evidence shows that the COVID-19 causative virus, SARS-CoV-2, penetrates the host cells by interacting with hosts' ACE2 receptor and TMPRSS2 protein., Once SARS-CoV-2 resides in host cells, the virus swiftly replicates, causing cytokine storm. During the cytokine storm, surge of cytokines release leads to persistent activation of immune cells by cytokines and piling up of cytokines at the inflammation site. High levels of cytokines are generated, including interferon (IFN), interleukin (IL), chemokines, colony-stimulating factors (CSFs), and tumor necrosis factor (TNF). Consequently, edema, fever, lung tissue injury, and congestion of the upper respiratory tract ensue. Increased activation of T-helper 17 (Th17) and cytotoxic CD8+ T-cells which resulted hypoimmunity in certain patients is also observed. Therefore, by inhibiting ACE2 and TMPRSS2, the transmission of SARS-COV-2 can be suppressed., On the other hand, attenuating cytokines storm can reduce lung injury and risk of fatality. Chai Hu (Radix Bupleurum), one of the ingredients forming Qing Fei Pai Du (lung-cleansing and toxin-removing) decoction and a recommended herbal formula for clearing damp-heat accumulation in the lung, contains the bioactive compound saikosaponins.,, An in silico analysis on saikosaponins identified that it disrupts the interaction between the spike protein of SARS-CoV-2 and ACE2 receptor, which then impairs the virus penetration into the host cells and blocks the virus replication. The active constituents in Huo Xiang Zheng Qi (Agastache qi-correcting), Jin Hua Qing Gan (honeysuckle flower cold-relieving) granule, Gan Cao (Glycyrrhizae Radix Rhizoma), and Huang Qin (Radix Scutellaria baicalensis) suppress the virus replication by binding to ACE2 and/or targeting 3CLpro., Another active compound in Dan Shen (Salviae miltiorrhizae), cryptotanshinone, represses the mRNA level of TMPRSS2 in vitro. Dan Shen (Salviae miltiorrhizae) is one of the constituents in Xue Bi Jing injection and a herbal formula recommended to treat Qi and Yin deficiency syndrome in the COVID-19 convalescent phase. Other recommended herbs that target cytokines include Ma Huang (Herba Ephedra), Xue Bi Jing injection, Reduning injection, Jin Hua Qing Gan (honeysuckle flower cold-relieving), and Tan Re Qing injection.
To date, over 90 China-based clinical trials examining the efficacy and safety of TCM for COVID-19 have been registered with the Chinese Clinical Trial Register (www.chictr.org.cn) and ClinicalTrials.gov. Table 1 details the registered clinical studies that are examining the recommended TCM treatment included in the treatment guideline. More than half of the registered studies (n = 56) evaluate the effects of ICWM, while 19 studies focused solely on the effects of TCM alone. Another 16 studies compared the effects between TCM and western medicine in managing COVID-19 patients. The most frequently examined TCM herbs are Xi Yan Ping injection (ChiCTR2000029756, ChiCTR2000030117, NCT04275388, ChiCTR2000030218, and NCT04295551), Lian Hua Qing Wen granule (Forsythiae and honey flower pestilence-clearing; ChiCTR2000029434, ChiCTR2000029433, and ChiCTR2000030478), Qing Fei Pai Du decoction (lung-cleansing and toxin-removing; ChiCTR2000030864, ChiCTR2000030806), Babaodan (pill of eight treasures) capsule (ChiCTR2000029819, ChiCTR2000029769), and Jin Yin Hua (Lonicerae Japonicae Flos) oral liquid (ChiCTR2000029954, ChiCTR2000030545). One study focused on the prevention of COVID-19 in the community, by analyzing the effect of Qing Hao (Artemisia) antipyretic granules and Huo Xiang Zheng Qi oral liquid (Agastache qi-correcting; ChiCTR2000029479). In a study administering Qing Fei Pai Du (lung-cleansing and toxins-removing) decoction twice daily to 98 newly confirmed cases of COVID-19 in the Sichuan province, laboratory tests returned to normal in over 70% of cases and a total effective rate of 84.2% was reported after 3 days of treatment. The total effective rate increased to 90.2% and 92.1%, after 6 days and 9 days of treatment, respectively. The chest computed tomographic scans of 79 patients showed improvement after treatment. Notably, none of the mild and moderate patients progressed to severe or critical cases, and there were no deaths.
Traditional Chinese medicine in preventing coronavirus disease 2019
Another hallmark of TCM is in the prevention of COVID-19. For suspected COVID-19 patients, five Chinese patent medicines have been recommended to alleviate symptoms during the observation period and have shown benefits in delaying disease progression. Huo Xiang Zheng Qi (Agastache qi-correcting) capsule is recommended for individuals with fatigue and gastrointestinal discomfort. However, for individuals experiencing fatigue and fever, Jin Hua Qing Gan (honeysuckle flower cold-relieving) granule, Lian Hua Qing Wen (Forsythiae and honeysuckle flower pestilence-clearing) capsule, Shu Feng Jie Du (wind-expelling and toxin-removing) capsule, and/or Fang Feng Tong Sheng (Saposhnikovia powder that sagely unblocks) pill are recommended. In vitro analysis of Lian Hua Qing Wen (Forsythiae and honey flower pestilence-clearing) showed that it exerts antiviral and anti-inflammatory effect on COVID-19 by blocking the replication of SARS-CoV-2 and downregulating the formation of pro-inflammatory cytokines (TNF-α, IL-6, CCL-2/MCP-1, CXCL-10/IP-10) at the mRNA level. Local health authorities in 23 provinces in China have recommended herbal medicine for COVID-19 prevention, principally composed of Huang Qi (Radix astragali), Gan Cao (Glycyrrhizae Radix Et Rhizoma), Fang Feng (Radix saposhnikoviae), Bai Zhu (Rhizoma Atractylodis Macrocephalae), and Jin Yin Hua (Lonicerae Japonicae Flos). External application of TCM, in the form of perfumed bags and feet bath, is also recommended. Offering preventive means to healthcare workers is vital as about 3.8% of the 44,672 COVID-19 cases were healthcare workers, of which 14.8% were severe or critical and among which were five deaths.
| Current Global Use of Traditional Chinese Medicine for Coronavirus Disease 2019|| |
The recent WHO-led international joint mission to fight COVID-19 in Italy, Iraq, and other countries provided a platform for Chinese experts to share their experiences in managing COVID-19 and to donate two TCM patent medications: Lian Hua Qing Wen (Forsythiae and honey flower pestilence-clearing) and Jin Hua Qing Gan (honeysuckle flower cold-relieving), to the involved countries. On April 14, 2020, Lian Hua Qing Wen (Forsythiae and honey flower pestilence-clearing) successfully registered in Hong Kong, Macau, Brazil, Indonesia, Romania, Thailand, Canada, and Mozambique under the classification of “Chinese patent medicine,” “drug,” “herbal medicine,” “natural health products,” food supplements,” and “modern plant medicine,” respectively.
Outside Mainland, China, other regions and countries have also used and promoted TCM for the prevention and treatment of COVID-19 in various ways. The School of Chinese Medicine of Hong Kong Baptist University offered discounted consultation fees and TCM herbal medicine at its 10 designated affiliated clinics, in efforts to assist in the prevention of COVID-19. However, the service could not be offered to individuals who had fever, returned from abroad, or with confirmed/suspected COVID-19 cases. To educate the public, they also promoted TCM methods to prevent COVID-19, such as TCM herbal remedies, Taichi exercises, and dietary advice based on the TCM theories. Overseas, the American College of Traditional Chinese Medicine at the California Institute of Integral Studies published information on using TCM to fight COVID-19 on their webpage. In view of limited registered TCM herbs in America, the author suggested to take Yu Ping Feng San (jade windscreen powder) for prevention and Bu Zhong Yi Qi Tang (tonify the middle and augment the qi decoction) when feeling weak but not sick. As for practitioners with TCM knowledge, San Ren Tang (three-seed decoction) with Xiao Chai Hu Tang (minor Bupleurum decoction) or Huo Xiang Zheng Qi (Agastache qi-correcting) decoction was suggested for early stages with damp constitution. LHSA OMS is a USA-based acupuncture needles and supplies company organized a webinar on the use of TCM to treat COVID-19. Taking into consideration that TCM herbs such as Ma Huang (Herba Ephedra) and Xi Xin (Herba Asari) are not available in the USA, the webinar also covered information on the substitution for those herbs.
In East Asian countries like Japan, the translated version of treatment guideline issued by the NHC of China was adopted. In Korea, both the Association of Korean Medicine and the Korean Association of Traditional Pulmonary Medicine had issued traditional medicine guidelines. The use of Sang Ju Yin (Mulberry leaf and Chrysanthemum decoction) and Yin Qiao San (honeysuckle and Forsythia powder) in mild cases and Qing Fei Pai Du (lung-cleansing and toxin-removing) decoction for severe COVID-19 cases was among the recommendations. In Malaysia, the Chinese Medicine School of INTI International University gave TCM advice to the public on staying healthy during the outbreak of COVID-19. University Tuanku Abdul Rahman joined forces with the TCM Expert Committee of Education Association between Malaysia and China, Beijing University of Chinese Medicine Malaysia Alumni Association, and the School of TCM of Xiamen University Malaysia to establish the Chinese Medicine Task Force of Malaysia (COVID-19). The mission of the task force is to provide TCM-related information on COVID-19, provide safety guidelines for TCM practitioners, and assist healthcare professionals. The Malaysian Alumni Association of Shanghai University of TCM had initiated free online TCM consultations and disseminated health information on COVID-19 during Malaysia's “movement control order.” Moreover, one clinical trial was registered in Malaysia (NMRR-20-759-54625) to examine the effects of adding TCM herbs to the standard Western Medicine in treating COVID-19 patients. This study was a collaboration between the Malaysia Ministry of Health, Sunway TCM Centre, and the Alumni Association of Shanghai University of TCM.
The global use of TCM to treat COVID-19 is still limited due to legislations, cultural barriers, and other various reasons. Nonetheless, given the experience in the use of TCM for treating SARS and the positive results from the treatment of COVID-10 with ICWM in China, the use of ICWM for COVID-19 can plausibly be expanded and recognized worldwide.
| Progress of Globalization of Traditional Chinese Medicine|| |
Since the establishment of the People's Republic of China in 1949, TCM has been inseparable from the national healthcare system, TCM hospitals have flourished, and the government has been continuously emphasizing the integration of TCM-western medicine. By 2016, China had TCM cooperation agreements with 86 countries and international organizations, backing the establishment of 10 TCM centers abroad. TCM has been gaining acceptance worldwide so much so that the export value of TCM added up to $3.72 billion in 2015, and the global value of the TCM market (including service and medicines) has been estimated to be worth over $50 billion. Under the Belt and Road Initiative, TCM was introduced to the involved countries through education, cultural exchanges, scientific research, and medical services. The WHO incorporated TCM in the International Statistical Classification of Diseases and Related Health Problems in 2019, thus acknowledging the contribution of TCM in healthcare and supporting the integration of TCM-western medicine. On a global scale, TCM is an integral part of complementary and alternative medicine (CAM), which comprehensively refers to nonmainstream medical treatment. CAM also includes other medicinal practices such as acupuncture, herbal medicine, Ayurveda, and Unani medicine. However, the acceptance of TCM and CAM outside China varies [Figure 1].
|Figure 1: Global prevalence of traditional Chinese medicine/complementary and alternative medicine usage. Schematic depiction with estimated general prevalence (red histogram), prevalence among children and adolescents (blue histogram) and selected information on traditional Chinese medicine/complementary and alternative medicine in some countries and regions worldwide (black box)|
Click here to view
Frequency of traditional Chinese medicine use
A review on the use of CAM in the general population among 15 countries reported a range from 5.8% (in Israel) to 76% (in Japan). The use of CAM was relatively higher in the general population in Asian countries, such as South Korea (75%), Malaysia (55.6%), and Singapore (44.6%). Outside Asia, the use of TCM was highest in Australia (68.9%). In a more focused study on 10,287 Australian elderly women, the authors revealed that 8.5% had used TCM, primarily for allergies, hay fever, sinusitis, severe fatigue, joint problem, digestion problem, and depression. Their countries of birth, visits to CAM practitioners, and use of self-prescribed CAM predominantly affected their use of TCM. In the Singapore National Health Surveillance Survey 2013, 26.5% had visited TCM practitioners at least once. More than half of the Taiwanese population (62.5%) used TCM, including nearly one quarter of its children population (22.5%), primarily for allergic rhinitis, dyspepsia, and musculoskeletal disease. Another systematic review on the use of CAM among 19 countries described a range from 0.8% to 85.5% of children, and adolescents populations had a history of taking herbal medicines; high CAM usage in Germany (85.5%), Brazil (63.8%), Turkey (58.6%) and very low in countries such as North America (12.1%), Ireland (8.7%) and UK (4.1%). Parental education and parental usage were related to high usage in children and adolescents.
Regulation of traditional Chinese medicine
The legislation of TCM differs across the countries. In the UK, over-the-counter (OTC) herbal medicines are regulated under the Traditional Herbal Medicines Regulation scheme, with similar requirements as that of conventional pharmaceutics, except the evidence of traditional use being submitted for verification of efficacy. Herbal medicines are available as unlicensed herbal remedies, registered herbal remedies, and licensed herbal medicines. As for Canada, herbal medicines are categorized as natural health products, governed by the Natural Health Products Regulations. As of 2012, over 56,000 natural health products have been registered in the Licensed Natural Health Products Database. In Europe, there are no specific regulations to register TCM, and herbal products can be marketed as food, cosmetics, traditional herbal medical products, medicines for human use or veterinary products. Conversely, in the United States, TCM is regulated as biological products, cosmetics, devices, or food under the Federal Food, Drug, and Cosmetic Act or Public Health Service Act. For TCM remedy to be registered as a new drug for disease treatment, well-designed clinical studies are required to provide evidence on its safety and efficacy and must comply with all regulatory requirements for new drugs. Other challenge when registering TCM as a new drug for disease treatment is the necessity to provide evidence on quality and therapeutic consistency, despite the complex composition of TCM herbs.
Treatment setting of traditional Chinese medicine
In China, TCM is widely provided in clinics, hospitals, and community health centers. The number of TCM hospitals across China summed up to 3966 at the end of 2015, with 446 ICWM hospitals. Of the 42,528 total TCM clinics in Mainland, China, 7706 clinics provided integrated TCM-western medicine. TCM expanded outside China, and there are currently about 100,000 TCM clinics globally. TCM in Hong Kong is commonly provided by private sector clinics, with only a few being under the tax-funded healthcare system, although a pilot TCM inpatient program is underway. Comparatively, TCM treatment has wider coverage in Taiwan, with 2 public TCM hospitals, 42 private TCM hospitals, and 2544 private TCM clinics. In Malaysia, TCM was initially provided by a charitable hospital in 1894. The Malaysia government hospitals later established four Traditional and Complementary Medicine Units offering TCM herbs to cancer patients, as supplementary to conventional cancer treatment. In Singapore and Australia, TCM treatment is predominantly provided in charitable clinics, private clinics,, or university teaching clinics. In Germany, a 76-bed TCM hospital was first founded in Kotzling, and later, TCM treatment was integrated in the outpatient clinic and wards of three pediatric hospitals.
| Challenges and Strategies in Extending Traditional Chinese Medicine Use to Coronavirus Disease 2019 and Other Infectious Disease|| |
Despite the evidence showing the benefits of TCM in the management of COVID-19, there are still many obstacles in expanding its global usage, which involve the legislation of TCM herbs, TCM distinct features, complexity of TCM herbs, integration of TCM-western medicine, as well as evidence-based usage of TCM [Figure 2]. Thus, in the quest of globalizing TCM usage, a multifaceted approach is warranted, particularly in addressing the registration and formulation of TCM herbs, as well as refining the quality of TCM herbs and clinical studies.
|Figure 2: Summary on challenges and strategies in extending traditional Chinese medicine use for coronavirus disease 2019|
Click here to view
Legislation issue of traditional Chinese medicine herbs
One of the biggest obstacles in globalizing TCM is that TCM herbs are not considered as medicines outside China. TCM herbs are largely marketed as natural health products or food supplements in countries such as Canada, Europe, and the USA, whereby the safety of TCM herbs is regulated in accordance with food standards. Clinical evidence of their effectiveness is not required, and these TCM herbs cannot be labeled and used for treatment. Furthermore, medical doctors are liable for malpractice when using non-FDA-approved drugs. In special cases, for example, in the current lack of targeted anti-COVID-19 treatment, medical doctors may cautiously use nonconventional treatments in the context of clinical trials, including the off-label use of registered drugs, such as antimalarial hydroxychloroquine and chloroquine., Among the TCM herbs outlined in the China national COVID-19 treatment guidelines, the principal herbs Ma Huang (Ephedra) is prohibited by the FDA due to safety concern while TCM injection is considered beyond the scope of food supplements.
Ideally, by harmonizing or narrowing down the disparities of regulations and standards among countries shall safeguard the public and allow worldwide usage of TCM herbs. However, matters such as standardizing the definition and categorizing TCM products (whether it is dietary supplement, OTC drug, traditional drug, or prescription drug) may first need to be ironed out. Although the unfavorable regulations for TCM herbs may not be changed anytime soon, TCM practitioners can legally provide TCM consultations and recommend TCM herbs to improve their patients' health.
Evidence-based of traditional Chinese medicine use
A search on PubMed found over 5000 TCM studies (as of April 24, 2020) on a wide range of topics. However, disparities between quantity and quality of TCM clinical studies exist, which necessitate improvement on quality of TCM clinical studies. Two systematic reviews on TCM randomized controlled trials (RCTs) published in China outlined the challenges that needed to be overcome for TCM clinical studies to gain credibility. The necessary improvement on methodology included improving methodology of RCT, providing sufficient details on intervention, well-defined method of randomization, adequate reporting, well-designed and performed trials with enough participants for subgroup analyses. Adopting Consolidated Standards for Reporting Trials (CONSORT) can improve the quality of RCT's reporting and providing sufficient and credible data for audience to appraise the RCTs. CONSORT checklist entails clear description on intervention, eligibility criteria for participants, allocation of participants, method of randomization, outcome measurement, sample size calculation, and other critical methodology. With clearly defined eligibility criteria of participants, selection bias is avoidable. While adequate data on methodology are required for reproducibility of the study, clarifying occurrence of adverse events shall provide a proper estimate on safety of TCM herbs. Good-quality clinical studies that prove the effectiveness and safety of TCM herbs are firm foundation for the globalization of TCM.
Integration of traditional Chinese medicine-western medicine
Integrating the treatments of TCM and western medicine is a challenging task. TCM and western medicine have been developed through different social and cultural backgrounds and have their respective advantages and limitations. However, they may be able to complement each other through integration. For instance, in managing COVID-19, targeted anti-COVID-19 western medical treatment is not yet available and the underlying mechanism of the virus has not yet been fully understood; however, the syndrome differentiation and holistic approach of TCM may provide management options or assistance. The use of Lian Hua Qing Wen (Forsythiae and honey flower pestilence-clearing) is supported by an in vitro study, showing that it has both antiviral and anti-inflammatory effects against SARS-CoV-2. Its anti-inflammatory activity of lowering the formation of proinflammatory cytokines is vital to downplay the cytokine storm that is responsible for causing critical conditions in COVID-19 patients. However, as TCM herbs may require time to exert effects, therapy plans combining western medicine could be adopted for faster clinical improvement. To promote communication and cooperation between TCM practitioners and western medicine clinicians, the ability of TCM practitioners to communicate using western medicine medical terms may be helpful.
As western medicine is the mainstay treatment for COVID-19 outside Mainland, China, the issue of herb–drug interaction may potentially arise from ICWM. Interactions may develop at the pharmacodynamic level where drug action is affected or at the pharmacokinetic level, whereby drug absorption, distribution, metabolism, and excretion are affected. A life-threating example is when there is concurrent consumption of a Dan Shen (Salviae miltiorrhizae)-containing formula with warfarin, which can aggravate the international normalized ratio and cause severe bleeding. However, it should be noted that beneficial herb–drug interaction has also been documented. For example, the antiviral activity of oseltamivir was increased when taken together with Yin Qiao San (honeysuckle and Forsythiae powder) or Sang Ju Yin (Mulberry leaf and Chrysanthemum decoction) formula, resulting in increased therapeutic effect without any untoward consequences.
Convincing western medicine healthcare professionals, policymakers, and stakeholders with rigorous scientific evidence is essential. The current situation compels TCM to engage in scientific experimental methods to explain the basis of TCM therapeutic effects, as well as to describe the active components, effective dose, onset of action, half-life, toxicity, adverse event, and mechanism of action of TCM herbs. These scientific data are necessary to mold the theoretical framework in guiding more scientific integration of TCM-western medicine. When conducting clinical studies, the aspects of herb–drug interactions need to be examined as well. By transparently reporting the results on treatment effectiveness and safety, the findings will guide both TCM and western medicine clinicians in providing herbal treatment with other drugs to attain therapeutic effect without affecting patients' safety.
Dosage forms, smell, and taste of traditional Chinese medicine herbs
The recommended TCM herbal formulae for COVID-19 consist up to 15 single herbs and are in the decoction form. Some patients may not be able to tolerate the smell, taste, and dosage form of TCM herbs. An Australian study indicated that patients were reluctant to take herbal preparations due to the inconvenient dosage form and unappealing smell and taste, which then lowered their adherence to herbal treatment. Recent development of TCM also emphasized on palatability issues of TCM herbs, as they affect patients' compliance and treatment effectiveness. Taste-masking technique applicable to oral formulation of TCM herbs is generally grouped into three categories: (i) excipient such as sweeteners, flavors, and bitter blockers in the formulation; (ii) polymer film-coating and lipid barrier systems to avoid bitter ingredients to come into contact with taste receptors; and (iii) binding charged polymers and ion-exchange resins to TCM drug molecules. TCM herb production sectors that are targeting the international market need to consider research and development for convenient dosage forms, favorable smell, and palatability.
| Conclusions|| |
COVID-19 is a new infection caused by coronavirus, with its pathophysiology and virology yet to be fully understood. Targeted anti-COVID-19 drugs and vaccines are still under development. Turning crisis into chance, this is an advantageous situation for TCM that applies syndrome differentiation treatment principles. Clinical studies involving large numbers of patients have shown that ICWM shortened recovery time and reduced mortality rate. In line with China's national treatment guidelines, TCM treatment was provided to 91.5% of COVID-19 patients and is one of the contributing factors to clinical improvement in more than 90% of COVID-19 patients and a considerably low fatality rate of about 4%. The global use of TCM for COVID-19 differs across countries due to various inherent constraints. To date, more TCM practitioners and institutions in countries outside China have offered TCM consultations, provided COVID-19 health-related information to the public, and promoted the use of locally registered TCM herbs. Although there is a clinical study outside China using combined TCM herbs with western medicine for COVID-19, the opportunities for TCM to be directly involved in treating COVID-19 patients are still limited outside China. To share and extend China's TCM experience in combating COVID-19, the situations and barriers in other countries need to be thoroughly understood and addressed accordingly. The recommended strategies to overcome the barriers include conducting quality scientific studies to provide robust scientific evidence, aligning China's regulations and standards on TCM herbs with international requirements, encouraging TCM practitioners to adopt appropriate language to communicate with western medicine healthcare professionals, and improving the formulation of TCM herbs.
The authors appreciated Dr. Hsiewe Ying (Amy) Tan for proofreading this manuscript
Financial support and sponsorship
This work was supported National Natural Science Foundation of China (Grant No. 81973438, 81803571) and National Major Scientific and Technological Special Project for “Significant New Drugs Development” (Grant No.2019ZX09301-140).
Conflicts of interest
There are no conflicts of interest.
| References|| |
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al
. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239-42.
Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med 2020;382:1969-73.
The State Council of the People's Republic of China. The State Administration of Traditional Chinese Medicine held a video conference on Traditional Chinese Medicine's Role on Prevention and Control System. The State Council of The People's Republic of China; 2020 Available from: http://www.gov.cn/xinwen/2020-01/24/content_5472008.htm
. [Last updated on 2020 Jan 24; Last accessed on 2020 Apr 17].
National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for Novel Coronavirus Pneumonia (Trial Version 7); Updated 3 March, 2020.
Wang L, Suo S, Li J, Hu Y, Li P, Wang Y, et al
. An investigation into traditional Chinese medicine hospitals in China: Development trend and medical service innovation. Int J Health Policy Manag 2017;6:19-25.
Liu X, Zhang M, He L, Li Y. Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS). Cochrane Database Syst Rev 2012;10:CD004882.
Chen Z, Nakamura T. Statistical evidence for the usefulness of Chinese medicine in the treatment of SARS. Phytother Res 2004;18:592-4.
Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, et al
. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med 2020;26:243-50.
Ang L, Lee HW, Choi JY, Zhang J, Soo Lee M. Herbal medicine and pattern identification for treating COVID-19: A rapid review of guidelines. Integr Med Res 2020;9:100407.
Zhao M, Chen Y, Wang C, Xiao W, Chen S, Zhang S, et al
. Systems pharmacology dissection of multi-scale mechanisms of action of Huo-Xiang-Zheng-Qi formula for the treatment of gastrointestinal diseases. Front Pharmacol 2018;9:1448.
Redeploying plant defences. Nat Plants 2020;6:177.
Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S, et al
. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 2020;156:104761.
Ren Y, Yao MC, Huo XQ, Gu Y, Zhu WX, Qiao YJ, et al
. Study on treatment of “cytokine storm” by anti-2019-nCoV prescriptions based on arachidonic acid metabolic pathway. Zhongguo Zhong Yao Za Zhi 2020;45:1225-31.
Li Y, Chang N, Han Y, Zhou M, Gao J, Hou Y, et al
. Anti-inflammatory effects of Shufengjiedu capsule for upper respiratory infection via the ERK pathway. Biomed Pharmacother 2017;94:758-66.
Song J, Zhang F, Tang S, Liu X, Gao Y, Lu P, et al
. A module analysis approach to investigate molecular mechanism of TCM formula: A Trial on Shu-feng-jie-du Formula. Evid Based Complement Alternat Med 2013;2013:731370.
Yuan Y, Liao Q, Xue M, Shi Y, Rong L, Song Z, et al
. Shufeng Jiedu capsules alleviate lipopolysaccharide-induced acute lung inflammatory injury via activation of GPR18 by Verbenalin. Cell Physiol Biochem 2018;50:629-39.
Tao Z, Gao J, Zhang G, Xue M, Yang W, Tong C, et al
. Shufeng Jiedu Capsule protect against acute lung injury by suppressing the MAPK/NF-κB pathway. Biosci Trends 2014;8:45-51.
Tao Z, Yang Y, Shi W, Xue M, Yang W, Song Z, et al
. Complementary and alternative medicine is expected to make greater contribution in controlling the prevalence of influenza. Biosci Trends 2013;7:253-6.
Wang R, Yang S, Xie C, Hen Q, Li M, Lei X, et al
. Clinical observation of qingfeipaidu decoction in the treatment of novel coronavirus pneumonia. Pharmacol Clin Chin Materia Med 2020;36:13-18.
Ren JL, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res 2020. pii: 155104743.
Luo E, Zhang D, Luo H, Liu B, Zhao K, Zhao Y, et al
. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): An empirical study from Wuhan, Hubei Province, China. Chin Med 2020;15:34.
Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 2020;14:64-8.
Zhang D, Zhang B, Lv JT, Sa RN, Zhang XM, Lin ZJ. The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence. Pharmacol Res 2020;157:104882.
Yang QW, Li Q, Zhang J, Xu Q, Yang X, Li ZY, et al
. Crystal structure and anti-inflammatory and anaphylactic effects of andrographlide sulphonate E in Xiyanping, a traditional Chinese medicine injection. J Pharm Pharmacol 2019;71:251-9.
Song Y, Yao C, Yao Y, Han H, Zhao X, Yu K, et al
. XueBiJing injection versus placebo for critically ill patients with severe community-acquired pneumonia: A randomized controlled trial. Crit Care Med 2019;47:e735-43.
Cao ZY, Chang XJ, Zhao ZP, Cao L, Xiao W. Antiviral effects of Reduning injection against Enterovirus 71 and possible mechanisms of action. Chin J Nat Med 2015;13:881-8.
Xiong L, Chen L, Wang C, Yue J, Li Y, Zhou W, et al
. Clinical efficacy and safety of tanreqing injection for pulmonary infection in patients with tuberculosis: A meta-analysis. J Altern Complement Med 2018;24:1051-62.
Zhang YM, Qu XY, Tao LN, Zhai JH, Gao H, Song YQ, et al
. XingNaoJing injection ameliorates cerebral ischaemia/reperfusion injury via SIRT1-mediated inflammatory response inhibition. Pharm Biol 2020;58:16-24.
Ding B, Fang B, Li J, Liu Q, Lv C, Yu X, et al
. Expert consensus guidelines on clinical use of Xiyanping injection for acute infectious diseases. Asian Pac J Trop Med 2020;13:152. [Full text]
Koo BS, Lee SI, Ha JH, Lee DU. Inhibitory effects of the essential oil from SuHeXiang Wan on the central nervous system after inhalation. Biol Pharm Bull 2004;27:515-9.
Liu H, Yan Y, Pang P, Mao J, Hu X, Li D, et al
. Angong Niuhuang Pill as adjuvant therapy for treating acute cerebral infarction and intracerebral hemorrhage: A meta-analysis of randomized controlled trials. J Ethnopharmacol 2019;237:307-13.
Liu H, Ye F, Sun Q, Liang H, Li C, Lu R, et al
. Scutellaria baicalensis
extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro
. bioRxiv 2020. doi: 10.1101/2020.04.10.035824.
Hoffmann M, Kleine-Weber H, Schroeder S, Krs252;ger N, Herrler T, Erichsen S, et al
. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-80.
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al
. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367:1260-3.
Yang CL, Qiu X, Zeng YK, Jiang M, Fan HR, Zhang ZM. Coronavirus disease 2019: A clinical review. Eur Rev Med Pharmacol Sci 2020;24:4585-96.
Sinha SK, Shakya A, Prasad SK, Singh S, Gurav NS, Prasad RS, et al
. An in silico
evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets. J Biomol Struct Dyn 2020:1-2. doi:10.1080/07391102.2020.1762741.
Li CC, Wang XJ, Wang HR. Repurposing host-based therapeutics to control coronavirus and influenza virus. Drug Discov Today 2019;24:726-36.
Ren X, Shao XX, Li XX, Jia XH, Song T, Zhou WY, et al
. Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach. J Ethnopharmacol 2020;258:112932.
Xu D, Lin TH, Li S, Da J, Wen XQ, Ding J, et al
. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells. Cancer Lett 2012;316:11-22.
Wang YX, Ma JR, Wang SQ, Zeng YQ, Zhou CY, Ru YH, et al
. Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19. Eur Rev Med Pharmacol Sci 2020;24:3360-84.
Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al
. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020;7:4.
State Administration of Traditional Chinese Medicine. Chinese Medicine “Goes Abroad” to Fight Epidemic! Large Number of Lianhu Qingwen, Jinhua Qinggan are donated to Italy Iraq. State Administration of Traditional Chinese Medicine; 2020. Available from: http://www.satcm.gov.cn/xinxifabu/meitibaodao/2020-03-15/13927.html
. [Last updated on 2020 Mar 15; Last accessed on 2020 Apr 15].
Hong Kong Baptist University Chinese Medicine. Special offer on consultation fees and Chinese Medicine during anti-epidemic period. Hong Kong Baptist University (HKBU) and Jockey Club Chinese Medicine Disease Prevention and Health Management Centre; 2020. Available from: https://embracehealth.org.hk/html/event_detail.php?id=76
. [Last accessed on 2020 Apr 14].
Hong Kong Baptist University Chinese Medicine. Arrangement of Clinic Appointment in Preventing COVID-19. Hong Kong Baptist University (HKBU) and Jockey Club Chinese Medicine Disease Prevention and Health Management Centre; 2020. Available from: https://embracehealth.org.hk/html/event_detail.php?id=77
. [Last updated on 2020 Apr 02; Last accessed on 2020 Apr 14].
Hong Kong Baptist University Chinese Medicine. Chinese Medicine in Prevention of COVID-19. Hong Kong Baptist University (HKBU) and Jockey Club Chinese Medicine Disease Prevention and Health Management Centre; 2020. Available from: https://embracehealth.org.hk/html/event_detail.php?id=68
. [Last accessed on 2020 Sep 23].
Shanghai University of Traditional Chinese Medicine. The Malaysian Alumni Association of SHUTCM Initiated a Free Online TCM Consultation Activity. Shanghai University of Traditional Chinese Medicine; 2020. Available from: http://www.shutcm.edu.cn/2020/0330/c973a121085/page.htm?from=timeline
. [Last updated on 2020 Mar 30; Last accessed on 2020 Apr 19].
Lam WC, Lyu A, Bian Z. ICD-11: Impact on traditional Chinese medicine and World Healthcare Systems. Pharmaceut Med 2019;33:373-7.
World Health Organization. WHO Global Report on Traditional and Complementary Medicine 2019. WHO; 2019.
Harris PE, Cooper KL, Relton C, Thomas KJ. Prevalence of complementary and alternative medicine (CAM) use by the general population: A systematic review and update. Int J Clin Pract 2012;66:924-39.
Sibbritt D, Adams J, Murthy V. The prevalence and determinants of Chinese medicine use by Australian women: Analysis of a cohort of 10,287 women aged 56-61 years. Am J Chin Med 2013;41:281-91.
Chen FP, Chen TJ, Kung YY, Chen YC, Chou LF, Chen FJ, et al
. Use frequency of traditional Chinese medicine in Taiwan. BMC Health Serv Res 2007;7:26.
Huang TP, Liu PH, Lien AS, Yang SL, Chang HH, Yen HR. A nationwide population-based study of traditional Chinese medicine usage in children in Taiwan. Complement Ther Med 2014;22:500-10.
Italia S, Wolfenstetter SB, Teuner CM. Patterns of complementary and alternative medicine (CAM) use in children: A systematic review. Eur J Pediatr 2014;173:1413-28.
Fan TP, Deal G, Koo HL, Rees D, Sun H, Chen S, et al
. Future development of global regulations of Chinese herbal products. J Ethnopharmacol 2012;140:568-86.
World Health Organization. WHO Traditional Medicine Strategy: 2014-2023. WHO; 2013.
Brosnan C, Chung VC, Zhang AL, Adams J. Regional influences on Chinese medicine education: Comparing Australia and Hong Kong. Evid Based Complement Alternat Med 2016;2016:6960207.
Kim YJ. The current studies of education for a traditional and complementary medicine in Malaysia. J Evid Based Complementary Altern Med 2017;22:531-7.
Lim RJ, Nik Nabil WN, Chan SY, Wong YF, Han LX, Gong JY, et al
. Effects of herbal medicine for xerostomia in head and neck cancer patients: An observational study in a tertiary cancer hospital. Support Care Cancer 2019;27:3491-8.
Melchart D, Hager S, Hager U, Liao J, Weidenhammer W, Linde K. Treatment of patients with chronic headaches in a hospital for traditional Chinese medicine in Germany. A randomised, waiting list controlled trial. Complement Ther Med 2004;12:71-8.
Eckert M, Amarell C, Anheyer D, Cramer H, Dobos G. Integrative pediatrics: Successful implementation of integrative medicine in a German hospital setting-concept and realization. Children (Basel) 2018;5:122.
Fung FY, Linn YC. Developing traditional Chinese medicine in the era of evidence-based medicine: Current evidences and challenges. Evid Based Complement Alternat Med 2015;2015:425037.
Li J, Liu Z, Chen R, Hu D, Li W, Li X, et al
. The quality of reports of randomized clinical trials on traditional Chinese medicine treatments: A systematic review of articles indexed in the China National Knowledge Infrastructure database from 2005 to 2012. BMC Complement Altern Med 2014;14:362.
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al
. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil Med Res 2020;7:11.
George J, Ioannides-Demos LL, Santamaria NM, Kong DC, Stewart K. Use of complementary and alternative medicines by patients with chronic obstructive pulmonary disease. Med J Aust 2004;181:248-51.
Zheng X, Wu F, Hong Y, Shen L, Lin X, Feng Y. Developments in taste-masking techniques for traditional Chinese medicines. Pharmaceutics 2018;10:157.
[Figure 1], [Figure 2]